跳至主要内容
临床试验/NCT05131087
NCT05131087已完成不适用

A First-In-Human Clinical Trial to Evaluate the Safety, Effectiveness and Surgical Characteristics of CADENCE in Patients With Refractory Glaucoma

New World Medical, Inc.1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2020年10月8日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
30
试验地点
1
主要终点
Assessment of AEs

研究概览

简要总结

To evaluate safety, effectiveness, and the surgical performance of CADENCE in patients with refractory glaucoma.

详细描述

CADENCE a single use implantable glaucoma drainage device used for the surgical treatment of refractory glaucoma. The device is implanted in the eye using an ab-externo approach

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
22 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •22-80 years of age.
  • •moderate to severe refractory glaucoma
  • •Able to consent

排除标准

  • •Women of child-bearing potential
  • •Intraocular surgery or laser within the last 3 months
  • •Ocular infection or inflammation within the last 6 months or currently active
  • •Current use of anti-coagulant therapy
  • •History of bleeding disorder or coagulopathies
  • •Subject plans to undergo any ocular surgery (including cataract surgery) during the study period
  • •History of corneal transplantation
  • •History of ICE Syndrome or epithelial ingrowth/downgrowth
  • •History of congenital glaucoma
  • •Elevated episcleral venous pressure
  • •. Persistent angle closure-
  • •Previous glaucoma filtration surgery- -Presence of conjunctival scarring -
  • •neovascular glaucoma
  • •AC lens or scleral sutured IOL
  • •inability to DC contact lenses
  • •Presence of intraocular silicone oil
  • •Vitreous in AC

研究组 & 干预措施

Cadence

Experimental

Cadence procedure

干预措施: Cadence implant (Device)

结局指标

主要结局

Assessment of AEs

时间窗: 12 months

comparison of intra-operative and post-operative adverse events observed to events reported in published literature,

次要结局

  • Surgical Experience Evaluation(12 months)
  • Change in IOP(12 months)
  • Change in IOP Lowering Medications(12 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验